<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of neurologic complications of platinum-based chemotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of neurologic complications of platinum-based chemotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of neurologic complications of platinum-based chemotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eudocia Quant Lee, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neurologic complications of anticancer therapy may result from direct toxic effects on the nervous system or indirectly from drug-induced metabolic derangements or cerebrovascular disorders. A wide range of neurologic complications are associated with antineoplastic drug treatment  (<a class="graphic graphic_table graphicRef55758" href="/d/graphic/55758.html" rel="external">table 1</a>) [<a href="#rid1">1-4</a>].</p><p>Their recognition is important because of potential confusion with metastatic disease, paraneoplastic syndromes, or comorbid neurologic disorders that do not require dose reduction or discontinuation. If the neurologic disorder is caused by the chemotherapy, discontinuation of the offending agent may prevent irreversible injury.</p><p>Among the widely used anticancer drugs, the platinum compounds <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> are most commonly associated with various forms of neurotoxicity. The incidence, clinical manifestations, possible mechanisms of neurotoxicity, and management of neurotoxicities other than peripheral neuropathy with cisplatin, oxaliplatin, and the less neurotoxic analog <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> will be reviewed here. The neurologic complications of other chemotherapy agents and biologic therapies, as well as preventive strategies and treatments for established chemotherapy-induced peripheral neuropathy, are discussed separately. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy"</a> and  <a class="medical medical_review" href="/d/html/2825.html" rel="external">"Neurologic complications of cancer treatment with molecularly targeted and biologic agents"</a> and  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CISPLATIN</span><span class="headingEndMark"> — </span>The range of cisplatin-induced neurotoxicity includes peripheral neuropathy, ototoxicity (hearing impairment and tinnitus), vestibulopathy, and encephalopathy; the most common are peripheral neuropathy and ototoxicity.</p><p class="headingAnchor" id="H3"><span class="h2">Peripheral neuropathy</span><span class="headingEndMark"> — </span>Symmetrical, predominantly sensory peripheral neuropathy is a common complication of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> therapy that develops in most patients typically only after a cumulative dose of 300 mg/m<sup>2</sup> is reached. Once established, there is no effective therapy, and treatment is symptomatic only. Most patients improve over time, although recovery is often incomplete.</p><p><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> causes an axonal neuropathy that predominantly affects large myelinated sensory fibers  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>) [<a href="#rid5">5-8</a>]. The primary site of damage is the dorsal root ganglion [<a href="#rid9">9</a>], although the peripheral nerve may also be affected.</p><p class="headingAnchor" id="H1201465871"><span class="h3">Incidence and risk factors</span><span class="headingEndMark"> — </span>Cisplatin-induced peripheral neuropathy is related to the total cumulative dose. Neuropathy usually develops only after a cumulative <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> dose beyond 300 mg/m<sup>2</sup>, and at a cumulative dose of 500 to 600 mg/m<sup>2</sup> almost all patients have objective evidence of neuropathy [<a href="#rid8">8,10,11</a>]; however, there is marked interindividual variation in susceptibility [<a href="#rid5">5,10,12</a>]. Genetic polymorphisms in some enzymes responsible for cisplatin metabolism (eg, glutathione S-transferase) may contribute to some of the observed interindividual differences in the incidence and severity of neuropathy [<a href="#rid13">13,14</a>]. Other conditions predisposing to neuropathy, such as diabetes, may contribute [<a href="#rid15">15</a>]. Higher cisplatin dose intensity (ie, higher doses per unit time) does not appear to enhance the severity of the neuropathy [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Clinical and electrophysiologic manifestations</span><span class="headingEndMark"> — </span>Clinically, cisplatin-induced peripheral neuropathy is characterized by the subacute development of numbness, paresthesias (abnormal sensations), and occasionally pain, which usually begins in the toes and fingers, spreading proximally to affect the legs and arms  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>). The earliest observable sign is a decreased vibratory sensitivity in the toes and loss of ankle jerks [<a href="#rid8">8</a>]. Although proprioception is impaired and reflexes are lost, pinprick, temperature sensation, and motor strength are usually spared, or less severely affected. Autonomic neuropathies are rare [<a href="#rid17">17</a>].</p><p>More prolonged treatment may worsen symptoms and signs with generalized loss of deep tendon reflexes, and more proximal vibratory sensory impairment. Lhermitte's sign, a shock-like sensation of paresthesias radiating from the back to the feet during neck flexion, is occasionally observed, typically after weeks or months of treatment [<a href="#rid18">18</a>]. It has also been reported in patients receiving high cumulative doses of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>. Lhermitte's sign is believed to result from transient demyelination of the posterior columns. (See <a class="local">'Oxaliplatin'</a> below.)</p><p>Nerve conduction studies show sensory axonal damage with decreased amplitude of sensory nerve action potentials (SNAP) and prolonged sensory latencies [<a href="#rid19">19,20</a>]. Motor nerve conduction velocities and compound muscle action potentials are typically unchanged during treatment. On sural nerve biopsy, both demyelination and axonal loss are evident.</p><p class="headingAnchor" id="H1201465877"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis includes paraneoplastic neuropathies and those associated with autoimmune disorders. Paraneoplastic neuropathies usually involve all sensory fibers, and there may be an antineuronal antibody (anti-Hu) in the serum. Patients with autoimmune neuropathies often have clinical features of an underlying connective tissue disease, and autoantibodies are usually present in the serum. Tetany in the hands and feet resulting from cisplatin-related electrolyte imbalance (ie, hypomagnesemia, hypocalcemia) may also be confused with peripheral neuropathy [<a href="#rid21">21</a>]. The symptoms of peripheral neuropathy may sometimes be confused with those of hand-foot syndrome (acral erythema), which can occasionally be seen with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. (See  <a class="medical medical_review" href="/d/html/5277.html" rel="external">"Evaluation of peripheral nerve and muscle disease"</a> and  <a class="medical medical_review" href="/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Subacute sensory neuronopathy'</a> and  <a class="medical medical_review" href="/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease"</a> and  <a class="medical medical_review" href="/d/html/142102.html" rel="external">"Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'</a>.)</p><p class="headingAnchor" id="H109349878"><span class="h3">Mechanism</span><span class="headingEndMark"> — </span>The major site of pathology is the dorsal root ganglion. <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> (and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (see <a class="local">'Oxaliplatin'</a> below)) enters into the dorsal root ganglion and binds to nuclear and/or mitochondrial DNA, causing apoptosis. There are two main mechanisms proposed to explain the pathophysiology of platinum-induced peripheral neuropathy:</p><p class="bulletIndent1"><span class="glyph">●</span>Platinum compounds form intrastrand adducts and interstrand crosslinks that alter the tertiary structure of the DNA [<a href="#rid22">22,23</a>]. This effect on DNA promotes alterations in cell-cycle kinetics, which leads to an attempt of differentiated postmitotic dorsal root ganglion neurons to re-enter the cell cycle, which leads to the induction of apoptosis [<a href="#rid24">24</a>]. <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">Oxaliplatin</a> forms fewer platinum-DNA adducts than does <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, and thus is slightly less neurotoxic [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second mechanism proposes involvement of oxidative stress and mitochondrial dysfunction as the trigger of neuronal apoptosis [<a href="#rid25">25-27</a>].</p><p></p><p>Regardless of the mechanism, apoptosis results in secondary damage to peripheral nerves.</p><p class="headingAnchor" id="H1201465946"><span class="h3">Natural history, prevention, and treatment</span><span class="headingEndMark"> — </span>Even if <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is discontinued, the sensory neuropathy continues to worsen for several months in 30 percent of patients (described as the "coasting" phenomenon) [<a href="#rid6">6,7,28</a>]. Neuropathy may even begin after therapy is discontinued. It eventually improves in most patients, although recovery is often incomplete [<a href="#rid28">28</a>]. In a study of long-term testicular cancer survivors who had completed treatment at least five years previously, peripheral neuropathy was still present in 20 percent, and 10 percent were symptomatic [<a href="#rid11">11</a>]. Higher levels of residual serum platinum, which can persist for years after treatment, appear to correlate with the severity of long-term peripheral neuropathy in cisplatin-treated survivors of testicular cancer [<a href="#rid29">29</a>]. In another report, factors that were related to a high risk for persistent neuropathy included age at diagnosis, smoking history, excess alcohol use, hypertension, and heritable factors [<a href="#rid30">30</a>].</p><p>There are no effective preventive strategies. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Preventive approaches'</a>.)</p><p>In general,<strong> </strong>patients with mild neuropathy can continue to receive full doses; however, if symptoms increase in severity or the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Sometimes, a patient can be switched to an alternative, less neurotoxic agent (eg, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>) if this is consistent with the goals of care. (See  <a class="medical medical_review" href="/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Carboplatin-based regimens'</a> and  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Carboplatin typically preferred over cisplatin'</a>.)</p><p>For some patients with platinum-induced neuropathy, pain is a prominent symptom. Amelioration of symptoms from the chronic neuropathy, including pain, may be achieved through use of antidepressants such as <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>. For symptomatic patients who fail to respond to duloxetine, other adjuvant analgesics (eg, tricyclic antidepressants, anticonvulsants), opioids, physical modalities such as cutaneous electrical stimulation, and/or interventional procedures may be indicated. Symptomatic treatment for chemotherapy-induced neuropathy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Specific interventions that are recommended'</a> and  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with neuropathic pain'</a> and  <a class="medical medical_review" href="/d/html/14249.html" rel="external">"Rehabilitative and integrative therapies for pain in patients with cancer", section on 'Other modalities'</a> and  <a class="medical medical_review" href="/d/html/14248.html" rel="external">"Interventional therapies for chronic pain"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Ototoxicity</span><span class="headingEndMark"> — </span>Ototoxicity is the second most common cisplatin-related neurotoxic effect; it is characterized by a dose-dependent, high-frequency sensorineural hearing loss, which is almost always bilateral and irreversible, and often accompanied by tinnitus and vertigo [<a href="#rid31">31,32</a>]. However, the exact incidence of tinnitus is unclear [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1201467360"><span class="h3">Incidence and risk factors</span><span class="headingEndMark"> — </span>Although ototoxicity is typically reported after intravenous <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> administration, it has also been seen after intraperitoneal use [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/3191.html" rel="external">"Intraperitoneal chemotherapy for treatment of ovarian cancer", section on 'Complications'</a>.)</p><p>The main risk factors are cumulative dose, age at treatment, and the use of concomitant ototoxic treatments. Incidence is variable and related to the specific diagnostic criteria used to define ototoxicity [<a href="#rid35">35</a>], the total dose of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, the use of concomitant ototoxic treatments, the population under study [<a href="#rid36">36</a>], and possibly inherited polymorphisms in drug metabolism genes:</p><p class="bulletIndent1"><span class="glyph">●</span>The influence of cumulative <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> dose was shown in an analysis of audiometric testing of 488 North American male germ cell tumor survivors [<a href="#rid37">37</a>]. Hearing loss was defined according to the American Speech-Language-Hearing Association (ASHA) criteria as a hearing threshold at any frequency (0.25 to 12 kHz) that exceeded 20 dB for either ear. At a median 51 months following chemotherapy, hearing loss was found in 80 percent of the survivors, and 18 percent had severe or profound hearing loss. Increasing cumulative cisplatin dose (median 400 mg/m<sup>2</sup>; range 200 to 800 mg/m<sup>2</sup>) was significantly related to hearing loss at 4, 6, 8, 10, and 12 kHz. Every 100 mg/m<sup>2</sup> increase in cumulative dose resulted in a 3.2 dB impairment in age-adjusted overall hearing threshold, and cumulative cisplatin doses &gt;300 mg/m<sup>2</sup> were associated with greater severity of hearing loss than were lower doses (odds ratio 1.59, p = 0.0066). Tinnitus (which was reported by 40 percent of survivors) was also significantly correlated with reduced hearing at each frequency.</p><p></p><p class="bulletIndent1">In another population-based study of significant hearing loss requiring hearing assistive devices (HADs) among childhood cancer survivors in Ontario, Canada, the cumulative incidence of needing a HAD at 20 and 30 years postdiagnosis was 2.1 and 6.4 percent, respectively [<a href="#rid38">38</a>]. The 30-year incidence was highest in neuroblastoma (10.7 percent, 95% CI 3.8-21.7 percent) and hepatoblastoma (16.2 percent, 95% CI 8.6-26 percent). In a multivariate analysis, children diagnosed at age zero to four had a twofold higher risk than did older children (hazard ratio 2.2, 95% CI 1.4-3.3 percent). Relative to no <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> exposure, those who received cumulative doses ≥200 mg/m<sup>2</sup> but not lower cumulative doses were at greater risk.</p><p></p><p class="bulletIndent1">Others report an elevated risk of cisplatin-induced hearing loss for cumulative <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> doses &gt;100 mg/m<sup>2</sup> and for higher fractionated doses in children [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although ototoxicity has a general dose dependence, there is considerable interindividual variability. Genetic polymorphisms in enzymes responsible for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> metabolism (eg, glutathione S-transferase [<em>GST</em>], thiopurine S-methyltransferase [<em>TPMT</em>], catechol O-methyltransferase [<em>COMT</em>]) may contribute to the observed interindividual differences in the severity of hearing loss [<a href="#rid40">40-46</a>]. Other candidate genes potentially involved in ototoxicity include excision repair cross-complementation groups 1 and 2 (<em>ERCC1</em> and <em>ERCC2</em>), acylphosphatasse-2 (<em>ACYP2</em>), solute carrier family 16 member 5 (<em>SLC16A5</em>), and the Mendelian deafness gene <em>WFS1</em> (wolframin ER transmembrane glycoprotein) [<a href="#rid47">47-51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher levels of residual serum platinum, which can persist for years following treatment, may also contribute to the severity of ototoxicity [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiotherapy (RT) to the normal cochlea or cranial nerve VIII can also cause sensorineural hearing loss. Concurrent administration of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and RT results in synergistic ototoxicity, especially in the high-frequency speech range [<a href="#rid52">52</a>]. The ototoxicity of combined modality therapy with cisplatin and RT is discussed in more detail separately. Care should be taken to distinguish sensorineural hearing loss versus conductive hearing loss due to serious otitis, an early complication of radiation. Conductive hearing loss can be treated. (See  <a class="medical medical_review" href="/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Ototoxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ototoxicity can be particularly severe in childhood cancer survivors [<a href="#rid36">36,53-56</a>]. Cofactors contributing to neurotoxicity include younger age (particularly &lt;5 years), the use of cranial irradiation, diagnosis of a central nervous system tumor, diminished renal function, high cumulative doses of platinum compounds, and the use of <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> in addition to <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> as part of the treatment regimen [<a href="#rid35">35,57</a>]. Whether longer infusion durations are associated with a lower incidence of platinum-induced ototoxicity is unclear [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">Although children may have a slightly greater capacity for improvement once treatment is discontinued, profound hearing impairment is not infrequent and can interfere with subsequent speech and language development [<a href="#rid36">36</a>], and impair neurocognitive function [<a href="#rid59">59,60</a>]. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors are available  (<a class="graphic graphic_table graphicRef120324" href="/d/graphic/120324.html" rel="external">table 3</a>) [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Monitoring for late or long-term effects of cancer and its treatment'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Mechanism</span><span class="headingEndMark"> — </span>The main targets of cisplatin- and carboplatin-related ototoxicity are the outer hair cells in the organ of Corti and the vascularized epithelium in the lateral wall of the cochlea [<a href="#rid42">42,63</a>].</p><p>This difference in risk of ototoxicity with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> has been attributed to lower cochlear uptake as compared with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid64">64</a>]. (See <a class="local">'Oxaliplatin'</a> below.)</p><p class="headingAnchor" id="H1415590843"><span class="h3">Grading and classification of hearing loss</span><span class="headingEndMark"> — </span>Several ototoxicity grading systems are currently in use  (<a class="graphic graphic_table graphicRef109907" href="/d/graphic/109907.html" rel="external">table 4</a>). There is substantial variability in the definition of the grades among the scales, and some are designed for use in children and others for adults. There is no consensus on the optimal tool nor frequency of assessment [<a href="#rid33">33</a>], although one analysis suggests superiority for the International Society for Pediatric Oncology (SIOP) scale [<a href="#rid65">65</a>]. At least in the United States, the Common Terminology Criteria for Adverse Events (CTCAE) scale is commonly used  (<a class="graphic graphic_table graphicRef117341" href="/d/graphic/117341.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H9"><span class="h3">Prevention</span></p><p class="headingAnchor" id="H1717704204"><span class="h4">Strategies</span><span class="headingEndMark"> — </span>Various strategies have been considered to minimize <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> ototoxicity:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and early detection</strong> – Early detection of ototoxicity in children receiving platinum agents may minimize the risk of severe impairment in the frequencies required for speech recognition by providing an opportunity for treatment modification, if possible before auditory damage becomes severe. Pure-tone audiometry is the standard method used for hearing assessment and generally involves the presentation of sounds across a wide spectrum of frequencies (500 to 8000 hertz [Hz]) [<a href="#rid66">66</a>]. In children being treated with either <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, extended high-frequency audiometry (ie, at frequencies above 8000 Hz [8 kHz]) is more sensitive to early hearing loss than conventional audiometry [<a href="#rid67">67</a>]. This procedure is readily carried out in children older than five years. For children less than five years of age, ototoxicity can be assessed using electrophysiologic techniques, such as brainstem auditory-evoked response [<a href="#rid66">66</a>]. Another option, distortion product otoacoustic emissions (DPOAEs) testing, is also more sensitive than conventional audiometry.</p><p></p><p class="bulletIndent1">Specific, consensus-based, age-appropriate recommendations for audiologic test batteries in children receiving ototoxic cancer treatment are available from the International Society of Paediatric Oncology [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic agents</strong> – We suggest the use of <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> (STS) for children receiving <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> monotherapy for a variety of non-metastatic malignancies, including standard-risk hepatoblastoma (cumulative dose 480 mg/m<sup>2</sup>). However, the safety and efficacy of this approach in patients with non-metastatic hepatoblastoma who receive lower cumulative doses is not established. (See  <a class="medical medical_review" href="/d/html/130011.html" rel="external">"Overview of hepatoblastoma", section on 'Approaches to minimizing long-term treatment-related toxicity'</a>.)</p><p></p><p class="bulletIndent1">The available evidence is insufficient to support the routine use of STS in children receiving <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> for treatment of a metastatic malignancy or in adults receiving cisplatin, or for any other pharmacologic agent to prevent cisplatin ototoxicity. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">Sodium thiosulfate</a> – Protection against platinum-induced hearing loss has been achieved in animal models and in patients (predominantly children) using STS [<a href="#rid69">69-72</a>]. The benefit of STS in children receiving <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> has been addressed in two randomized trials:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the Children's Oncology Group (COG) ACCL0431 trial, 125 children receiving <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> for a variety of malignancies (germ cell cancer, medulloblastoma, neuroblastoma, osteosarcoma) who were not registered in a cancer-directed COG therapeutic study were randomly assigned to a single dose of STS six hours after each cisplatin dose or to observation [<a href="#rid71">71</a>]. The use of STS was associated with a significantly smaller proportion of patients with hearing loss four weeks after the final cisplatin dose (29 versus 56 percent, odds ratio of hearing loss 0.31, 95% CI 0.13-0.73).</p><p></p><p class="bulletIndent3">Therapy was well tolerated, with no serious adverse events deemed probably or definitely related to STS. However, there were also concerns about inferior disease outcomes in the STS group (three-year event-free survival 54 versus 64 percent, overall survival 70 versus 87 percent), raising concern for a possible tumor protective effect with administration of STS. In a post hoc subgroup analysis, the inferior survival appeared to be limited to those with disseminated disease (three-year overall survival 45 versus 84 percent, relative hazard ratio 4.10, 95% CI 1.30-12.97).</p><p></p><p class="bulletIndent3">Although it was postulated that better than expected outcomes in the control group with short-term follow-up might have been responsible for the apparent survival detriment with STS in those with disseminated disease (ie, that the results were an artifact of short follow-up), the detrimental impact of STS on overall survival persisted with longer-term follow-up (six-year overall survival 45 versus 73 percent, HR for death 2.74, 95% CI 1.01-7.44) [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Benefit was confirmed, but without jeopardizing cancer outcomes, in the randomized phase III <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00652132%3Fterm%3Dhepatoblastoma%2Band%2Bsodium%2Bthiosulfate%26rank%3D2&amp;token=do44EbLIKHuI5zRNQpGqYXPGmpKQYkIeEEk3biBj2A%2BYlHhtLeqWFtVqa%2BVmL45AYI6JmuhKkT2%2BjlavJ8QF8PlyLROxUWhPmNaHwC34HounbL9gZn03X9zp8BLhbDOjbK1raGoKGpkXwKPImqXgCg%3D%3D&amp;TOPIC_ID=2826" target="_blank">SIOPEL-6</a> trial, in which 109 children with standard-risk hepatoblastoma receiving single-agent <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> were randomly assigned to receive or not receive STS (administered at various doses of 10 g/m<sup>2</sup>, 15 g/m<sup>2</sup>, or 20 g/m<sup>2</sup> based on actual body weight, over 15 minutes, six hours after each cisplatin dose) [<a href="#rid72">72</a>]. The addition of STS resulted in a significant reduction in the incidence of cisplatin-induced hearing loss (39 versus 68 percent, HR 0.58, 95% CI 0.40-0.83). At a median follow-up of 52 months, cancer outcomes were not worse in the STS group, but these patients did not have disseminated disease. (See  <a class="medical medical_review" href="/d/html/130011.html" rel="external">"Overview of hepatoblastoma", section on 'Approaches to minimizing long-term treatment-related toxicity'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A meta-analysis of these two studies and a third trial that examined intravenous STS [<a href="#rid70">70</a>] concluded that STS was effective at preventing <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> ototoxicity (risk ratio 0.57, 95% CI 0.45-0.73) [<a href="#rid74">74</a>]. When the analysis was limited to the two trials conducted in children, event-free survival (hazard ratio [HR] 1.13, 95% CI 0.70-1.82) and overall survival (HR 1.90, 95% CI 0.90-4.03) were not significantly worse with STS; however, the range of the confidence intervals was wide and the authors concluded that additional large scale studies were indicated to assess impact on survival outcomes.</p><p></p><p class="bulletIndent2">Largely based on these two studies, STS has been approved by the US Food and Drug Association (FDA) as treatment to help decrease the risk of cisplatin-related ototoxicity in pediatric patients aged one month or older who have received a diagnosis of localized, non-metastatic solid malignancies [<a href="#rid75">75</a>]. The approved dose is based on actual body weight, as outlined in the United States Prescribing Information [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Amifostine</strong> – Whether <a class="drug drug_general" data-topicid="8533" href="/d/drug information/8533.html" rel="external">amifostine</a> offers protection in children receiving <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is unclear. Benefit has been suggested in some [<a href="#rid77">77,78</a>] but not all uncontrolled trials [<a href="#rid79">79</a>], while two small randomized trials (one in patients with osteosarcoma, the other in hepatoblastoma) failed to show benefit for prophylactic amifostine [<a href="#rid80">80,81</a>]. An updated 2016 Cochrane review concluded that the data were insufficient to make any definite conclusions as to amifostine efficacy or lack thereof [<a href="#rid82">82</a>]. 2008 guidelines from the American Society of Clinical Oncology (ASCO) also concluded that the data were insufficient to support the routine use of amifostine to prevent cisplatin ototoxicity [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> – Animal models suggest a potential protective effect of vitamin E against ototoxicity [<a href="#rid84">84</a>]. Only limited data are available in humans. One double-blind trial randomly assigned 108 patients initiating treatment for a solid tumor with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> to receive vitamin E (400 mg daily) or an identical placebo, with both treatments administered daily during cisplatin and for three months thereafter [<a href="#rid85">85</a>]. Unfortunately, only 23 were included in the final analysis; 40 dropped out early on (predominantly because of disease progression), 27 were excluded because the cumulative cisplatin dose was &lt;300 mg/m<sup>2</sup>, and of the remaining 41, 18 completed only one visit and were not included in the statistical analysis. At one-month audiography, the control group had significant hearing loss in both ears, while there were no significant changes in the active group. Interpretation of this trial is severely limited by the high number of dropouts and the lack of information on preintervention and postintervention serum vitamin E levels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intratympanic treatments</strong> – A benefit for intratympanic glucocorticoid injections was suggested in a small trial in which 28 patients age &lt;18 years, with a neoplastic disease for which the curative intent protocol included <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, had local injection of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> into a randomly assigned middle ear; the other ear of the same patient served as the control [<a href="#rid86">86</a>]. Of the 15 patients who completed the study, compared with the control ears, ears with intratympanic dexamethasone had significantly attenuated hearing loss at 6000 Hz and decreased outer hair dysfunction as measured by differences in the Audiometry and Distortion Product Otoacoustic Emissions tests (DPOAEs) at baseline and at one week after the cumulative dose of cisplatin reached 400 mg. Although these results are promising, additional data in a larger number of patients and longer-term observations are needed before concluding that there is benefit from this invasive procedure.</p><p></p><p class="bulletIndent2">In addition, three small trials have explored the benefit of intratympanic <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, two of which were conducted entirely in adults, and two of which suggested potential benefit [<a href="#rid87">87-89</a>]. A systematic review concluded that efficacy conclusions were limited by the small sample sizes, open-label designs, and lack of direct comparison of ears using paired tests [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diethyldithiocarbamate</strong> – Three trials, all conducted in adults, failed to show any benefit from diethyldithiocarbamate and disulfiram, both thiol heavy metal chelating agents, as protectants against <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> ototoxicity [<a href="#rid91">91-93</a>].</p><p></p><p>A major challenge to the development of effective otoprotective agents is the lack of consensus on the best ototoxicity assessment criteria [<a href="#rid42">42,94</a>]. (See <a class="local">'Grading and classification of hearing loss'</a> above.)</p><p class="headingAnchor" id="H3953178220"><span class="h4">Guidelines from expert groups</span><span class="headingEndMark"> — </span>Evidence-based guidelines for prevention of cisplatin-induced ototoxicity in children and adolescents with cancer are available from a multidisciplinary multinational expert panel [<a href="#rid95">95</a>]. Regarding the use of <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a>, the panel made a strong recommendation for its use in patients treated for non-metastatic hepatoblastoma, a weak recommendation for its use in other non-metastatic cancers, and a weak recommendation against its use in patients with metastatic cancer. Despite these recommendations, unfortunately, a suitable sterile formulation of sodium thiosulfate for this use is not yet commercially available in any country. The panel also made a strong recommendation against the use of <a class="drug drug_general" data-topicid="8533" href="/d/drug information/8533.html" rel="external">amifostine</a>, sodium diethyldithiocarbamate, and intratympanic therapy in any setting.</p><p class="headingAnchor" id="H11"><span class="h2">Encephalopathy</span><span class="headingEndMark"> — </span>Encephalopathy is rare and has been observed most often after intra-arterial administration [<a href="#rid96">96</a>]. Symptoms include seizures and focal neurologic symptoms, including cortical blindness [<a href="#rid97">97,98</a>]. The encephalopathy is associated with reversible abnormalities in the white matter of the occipital, parietal, and frontal lobes (reversible posterior leukoencephalopathy). (See  <a class="medical medical_review" href="/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p>Cisplatin-induced encephalopathy must be distinguished from metabolic causes, including water intoxication caused by prehydration, treatment-induced renal impairment, hypomagnesemia, hypocalcemia, and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Paraneoplastic SIADH may accompany some malignancies for which <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is commonly used, particularly small cell lung cancer. Rare cases of cisplatin-induced SIADH are reported [<a href="#rid99">99,100</a>]. (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a> and  <a class="medical medical_review" href="/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a> and  <a class="medical medical_review" href="/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Other complications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> has been associated with a number of other neurologic complications, including:</p><p class="bulletIndent1"><span class="glyph">●</span>A vestibulopathy, resulting in ataxia and vertigo, dysgeusia, and a myasthenic syndrome [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive impairment [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/16347.html" rel="external">"Cognitive function after cancer and cancer treatment", section on 'Neurobiologic basis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The development of hiccups in patients receiving cisplatin-based regimens. Although <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> may contribute to this toxicity, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> also appears to play a causative role [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/6892.html" rel="external">"Hiccups", section on 'Medication-induced'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guillain-Barré syndrome is rarely reported [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intracarotid <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> infusion may be associated with optic neuritis and retinopathy [<a href="#rid17">17,104</a>]. By contrast, cisplatin does not appear to interfere with olfactory function [<a href="#rid105">105</a>]. Focal lumbosacral plexopathy or mononeuropathy has been reported following infusion of the internal or external iliac arteries [<a href="#rid106">106</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h1">CARBOPLATIN</span></p><p class="headingAnchor" id="H1386733595"><span class="h2">Peripheral and central nervous system toxicity</span><span class="headingEndMark"> — </span>Peripheral neuropathy and central nervous system toxicity are uncommon when <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is given at conventional doses  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>). However, a severe neuropathy can develop after higher than standard-dose carboplatin, as used in the setting of high-dose therapy with hematopoietic cell transplantation [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H1386733583"><span class="h2">Hearing loss</span><span class="headingEndMark"> — </span>In adults, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is less ototoxic than is <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid108">108</a>], although ototoxicity can still occur with high-dose (myeloablative) therapy [<a href="#rid109">109-111</a>].</p><p>Ototoxicity has been more prominent in younger children (especially infants), but not in all studies:</p><p class="bulletIndent1"><span class="glyph">●</span>The administration of <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> to children treated for retinoblastoma usually does not lead to acute or subacute hearing loss [<a href="#rid112">112-114</a>]. In one of these studies, hearing loss affected only 5 percent of patients at a median of 3.7 years after treatment [<a href="#rid114">114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, much higher rates of ototoxicity were reported in another study of 60 children receiving <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> for retinoblastoma [<a href="#rid109">109</a>]. Twelve (20 percent) developed ototoxicity at a median of eight months after the start of therapy, and nine required hearing aids. The only factor that predicted sustained hearing loss was younger age at start of treatment (median age at treatment initiation of the patients who developed hearing loss versus those who did not was 2.3 versus 10.3 months).</p><p></p><p>One of the reasons hypothesized to account for these findings was the dosing of <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> based upon body surface area (BSA) rather than body weight alone. Particularly in small children weighing &lt;10 kg, this could result in exposure to potentially toxic serum levels of drugs [<a href="#rid115">115</a>]. The common practice of normalizing chemotherapy doses to weight rather than BSA in infants weighing &lt;10 kg (which was done in the other three studies [<a href="#rid112">112-114</a>]) results in lower doses that offset differences in drug disposition and end organ sensitivity. (See  <a class="medical medical_review" href="/d/html/107561.html" rel="external">"Retinoblastoma: Treatment and outcome", section on 'Hearing'</a>.)</p><p>Long-term audiometric follow-up is advisable for all children who receive <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> for treatment of retinoblastoma. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors are available  (<a class="graphic graphic_table graphicRef120324" href="/d/graphic/120324.html" rel="external">table 3</a>) [<a href="#rid61">61,62</a>]. (See <a class="local">'Ototoxicity'</a> above.)</p><p class="headingAnchor" id="H1386733589"><span class="h2">Other manifestations</span><span class="headingEndMark"> — </span>Other manifestations of neurotoxicity from <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> include a microangiopathic hemolytic anemia resulting in progressive neurologic impairment and death [<a href="#rid116">116</a>], reversible posterior leukoencephalopathy syndrome [<a href="#rid117">117</a>], Guillain-Barré syndrome [<a href="#rid103">103</a>], and retinal toxicity following intra-arterial administration for brain tumors [<a href="#rid118">118</a>].</p><p class="headingAnchor" id="H15"><span class="h1">OXALIPLATIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">Oxaliplatin</a> is a third-generation platinum compound used in the treatment of several gastrointestinal malignancies, most notably metastatic colorectal cancer (CRC). (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'FOLFOX versus FOLFIRI'</a>.)</p><p class="headingAnchor" id="H1201467695"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Two distinct syndromes have been reported: an acute neurosensory complex, which can appear during or shortly after the first few infusions, and a cumulative sensory neuropathy, with distal loss of sensation and dysesthesias  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>). Neuromotor toxicity is much less common. Ototoxicity is rare with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, unlike <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid119">119</a>].</p><p>Other rare manifestations of neurotoxicity include urinary retention and Lhermitte's sign, which have been reported in patients receiving high cumulative <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> doses [<a href="#rid120">120,121</a>]. Reversible posterior leukoencephalopathy is also reported [<a href="#rid122">122-124</a>]. (See  <a class="medical medical_review" href="/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Acute neurotoxicity</span><span class="headingEndMark"> — </span>The majority of patients treated with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (&gt;85 percent in two reports [<a href="#rid125">125,126</a>]) experience symptoms of acute neurotoxicity. Typical symptoms include discomfort swallowing cold items; throat discomfort; sensitivity to touching cold items; paresthesias and dysesthesias of the hands, feet, and perioral region; and muscle cramps [<a href="#rid127">127,128</a>]. Numbness and tingling are more prominent than shooting or burning pain [<a href="#rid127">127</a>] Symptoms generally evolve over 24 to 96 hours, and typically abate over the same time frame [<a href="#rid127">127</a>].</p><p>In addition to muscle cramps, other motor symptoms that may develop include jaw tightness, voice changes, ptosis, visual field abnormalities, and, rarely, priapism  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>) [<a href="#rid129">129</a>]. One case report suggests that acute motor symptoms may be particularly responsive to treatment with oral <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> (Lyrica) [<a href="#rid130">130</a>].</p><p>The range and frequency of oxaliplatin-induced acute neurotoxicity from a series of 170 patients treated with an oxaliplatin-based regimen for metastatic CRC, 146 of whom (86 percent) manifested any degree of acute neuropathy, was as follows [<a href="#rid125">125</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cold-induced perioral paresthesias – 95 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cold-induced pharyngolaryngeal dysesthesia – 92 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea – 40 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle cramps – 34 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Jaw stiffness – 34 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia – 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Visible fasciculations – 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Voice changes – 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Ocular changes – 0.7 percent</p><p></p><p>Acute symptoms are observed more frequently at doses of ≥130 mg/m<sup>2</sup> than at ≤85 mg/m<sup>2</sup> and are infusion-rate dependent [<a href="#rid131">131</a>]. Increasing the duration of infusion from two to six hours during subsequent treatments has been reported to diminish the incidence, particularly of the pseudolaryngospasm [<a href="#rid132">132</a>]. While it has been classically thought that acute neuropathy completely resolves after a few days, more recent data support the view that it does not completely resolve between <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> doses, at least with repeat dosing every two weeks [<a href="#rid126">126</a>].</p><p>Symptoms tend to recur with subsequent doses. On average, symptoms are twice as severe after the second dose as compared with the first dose, but thereafter, symptom intensity remains similar for all subsequent doses; acute neurotoxicity does not appear to worsen cumulatively over time [<a href="#rid126">126</a>]. Patients with the most severe acute symptoms are at higher risk to develop more severe chronic neuropathy. (See <a class="local">'Other factors'</a> below.)</p><p class="headingAnchor" id="H1201467810"><span class="h4">Mechanism</span><span class="headingEndMark"> — </span>Acute neurotoxicity caused by <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> is thought to result from chelation of calcium by oxalate (a metabolite of oxaliplatin) with transient activation of disinhibited peripheral nerve voltage-gated calcium-dependent sodium channels causing hyperexcitability of peripheral nerves [<a href="#rid133">133,134</a>]. This has been attributed to disruption in cell membrane ion channels [<a href="#rid135">135-140</a>]. Acute changes in axonal excitability seem to become less pronounced in later treatment cycles, possibly because chronic nerve dysfunction and sensory loss mask the acute effects at higher cumulative doses [<a href="#rid138">138</a>].</p><p class="headingAnchor" id="H374439248"><span class="h4">Prevention</span><span class="headingEndMark"> — </span>Supplemental calcium and magnesium infusions are of no benefit and should not be offered to patients receiving <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> therapy. This subject is addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Vitamins, minerals, and dietary supplements'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Cumulative sensory neuropathy</span><span class="headingEndMark"> — </span>The dose-limiting, late-onset neuropathy seen with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> is comparable to that observed with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. Characteristically, this is a cumulative, dose-dependent, sensory, symmetric distal axonal neuropathy without motor involvement, and with rare autonomic [<a href="#rid141">141</a>] involvement  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>). In an analysis of 346 patients treated with oxaliplatin in the phase III Alliance trial N08CB, tingling was the most severe symptom, followed by numbness, and then pain [<a href="#rid126">126</a>].</p><p>Oxaliplatin-related neuropathy can have a profound impact on quality of life, particularly that of cancer survivors. It may also adversely affect oncologic outcomes by forcing dose modifications and/or premature treatment discontinuation.</p><p>The mechanism of neuropathy appears similar to that discussed for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, although <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> forms fewer platinum-DNA adducts then does cisplatin, and thus is a slightly less neurotoxic agent [<a href="#rid22">22</a>]. (See <a class="local">'Mechanism'</a> above.)</p><p class="headingAnchor" id="H18"><span class="h4">Incidence, severity, risk factors, and natural history</span><span class="headingEndMark"> — </span>The incidence and severity are predominantly related to cumulative dose, although other factors (eg, diabetes, severity of acute neuropathy) may contribute [<a href="#rid15">15</a>]. Patients with more severe acute neurotoxicity during the first cycle of therapy may experience more chronic sensory toxicity [<a href="#rid126">126</a>].</p><p>In general, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> neurotoxicity improves after discontinuation of therapy. However, it may continue to worsen for a few months after treatment is discontinued (a phenomenon referred to as "coasting"). Neuropathy is at least partially reversible in approximately 80 percent of patients; one-half of these patients report complete resolution within eight months after treatment discontinuation [<a href="#rid142">142</a>]. However, higher rates of persisting neuropathy are reported by others, particularly in studies utilizing patient-reported outcome measures. In general, hand symptoms are more severe during therapy while feet symptoms become more prominent during follow-up [<a href="#rid126">126</a>].</p><p class="headingAnchor" id="H1386733718"><span class="h5">Impact of dose intensity and length of treatment</span><span class="headingEndMark"> — </span>In the adjuvant setting, higher dose intensity therapy (ie, doses above 85 mg/m<sup>2</sup> every two weeks) has not been associated with a greater incidence or severity of neurotoxicity [<a href="#rid143">143</a>].</p><p>In the setting of metastatic disease, patients are often treated for longer than six months, and neuropathy increases with a longer planned treatment duration [<a href="#rid144">144-146</a>]. As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective trial in which patients received <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> 85 mg/m<sup>2</sup> per cycle in conjunction with short-term infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, severe (grade 2 or 3) neuropathy occurred in 10 percent of patients after nine, in 25 percent after 12, and in 50 percent after 14 treatment cycles [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1">These findings have important implications for clinical care. Clinicians should be particularly vigilant about routinely assessing sensory neuropathy after approximately four months of therapy with an oxaliplatin-based regimen containing 85 mg/m<sup>2</sup> <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> every two weeks. The use of oxaliplatin-free intervals in patients treated for metastatic CRC as a means of delaying or preventing neuropathy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'Patients receiving oxaliplatin'</a>.)</p><p></p><p class="headingAnchor" id="H1386733943"><span class="h5">Other factors</span><span class="headingEndMark"> — </span>Whether other clinical factors are useful in predicting higher rates or greater severity of oxaliplatin-related peripheral neuropathy is unclear [<a href="#rid147">147</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have a more severe or more complex combination of acute neuropathy phenomenon are at higher risk for more severe chronic cumulative neuropathy [<a href="#rid125">125,127,146</a>]. In a prospective study of 200 patients with metastatic CRC receiving 24 weeks of an oxaliplatin-based regimen who underwent electrophysiologic testing at baseline, mid-treatment, and at the end of treatment, multivariate analysis disclosed three factors that were independently associated with the risk of developing severe (grade 3 or worse) <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> sensory neuropathy: the number of acute neurotoxicity symptoms and a &gt;30 percent decrease (from the baseline value) in sensory nerve action potentials in radial and dorsal sural nerves at midcycle [<a href="#rid146">146</a>]. Although this study suggests potential for benefit, the value of serial nerve conduction studies in patients receiving oxaliplatin is not established, and we generally don't use them. (See <a class="local">'Acute neurotoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes increases the risk for neuropathy, but there is disagreement as to whether such patients have more severe neuropathy, or develop it at a lower cumulative <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> dose [<a href="#rid148">148,149</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At least some data suggest that the specific fluoropyrimidine paired with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> may influence the risk of neurotoxicity:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a report of the ACHIEVE trial, which compared three versus six months of adjuvant oxaliplatin-based chemotherapy, those patients treated with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus the oral drug <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (CAPOX) had a lower incidence of persisting peripheral sensory neuropathy at three years than did those receiving oxaliplatin in conjunction with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> and short-term infusional <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (the FOLFOX regimen), regardless of whether they received six months of treatment (21 versus 34 percent) or three months of treatment (7.9 versus 15.7 percent) [<a href="#rid150">150</a>]. (See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer", section on 'Oxaliplatin-based therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A similar finding was noted in an earlier analysis of 150 patients receiving either FOLFOX or CAPOX in either the adjuvant or metastatic disease setting [<a href="#rid151">151</a>]. FOLFOX was associated with a higher incidence of chronic neurotoxicity (83 versus 60 percent), despite a very similar median cumulative dose of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> during both regimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other factors, including body mass index and lower level of physical activity may also contribute [<a href="#rid149">149</a>].</p><p></p><p class="headingAnchor" id="H1386733964"><span class="h5">Molecular predictors</span><span class="headingEndMark"> — </span>Inheritance of certain polymorphisms may influence the risk of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> neurotoxicity [<a href="#rid152">152-157</a>], although the data are conflicting [<a href="#rid158">158</a>]. Whether pharmacogenetic profiling may hold some promise for identifying patients at a greater risk for severe neurotoxicity is unclear, and the data are insufficient to justify routine testing for any specific genotype prior to initiating oxaliplatin.</p><p class="headingAnchor" id="H93783210"><span class="h5">Natural history</span><span class="headingEndMark"> — </span>Data on natural history are available from several sources:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSABP C-07</strong> – The phase III The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial randomly assigned 2492 patients to six months of adjuvant <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> with or without <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (85 mg/m<sup>2</sup> on weeks 1, 3, and 5 of each of three eight-week cycles) after surgery for colon cancer, including 400 who participated in a patient-reported substudy [<a href="#rid159">159</a>]. (See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer", section on 'FLOX and NSABP C-07'</a>.)</p><p></p><p class="bulletIndent1">The following findings were noted with respect to neurotoxicity:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient-reported neurotoxicity was significantly more common in patients receiving <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, including sensory symptoms (hand-foot pain, 26 versus 3 percent without oxaliplatin) and moderate motor weakness (27 versus 16 percent). Although hand symptoms generally resolved by 18 months, foot numbness and tingling persisted in many (prevalence 22 versus 5 percent in those not receiving oxaliplatin).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a later analysis of 353 of these patients who had longitudinal data on neurotoxicity and were reassessed at a median of six years after random assessment, the group receiving <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> had statistically significantly higher total neurotoxicity scores compared with those not receiving oxaliplatin (a difference of 1.8 points on a point scale ranging from 0 to 48) [<a href="#rid160">160</a>]. However, this difference was not clinically meaningful. These authors had previously proposed that a difference of four on this patient-reported scale should be considered a minimal clinically significant difference [<a href="#rid159">159</a>], although this has not been validated by others. When separate categories of neurotoxicity were assessed, the odds of persistent numbness and tingling in the hands or feet was 2 to 2.78-fold higher in those who received oxaliplatin versus those who did not receive oxaliplatin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MOSAIC trial</strong> – Information on the reversibility of neurotoxicity is also available from the MOSAIC trial, a randomized comparison of short-term infusional leucovorin-modulated <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> with and without <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (85 mg/m<sup>2</sup> every other week for 24 weeks) as adjuvant chemotherapy after colon cancer resection [<a href="#rid161">161</a>]. Although some form of peripheral neuropathy developed in 92 percent of patients receiving oxaliplatin, it was severe (grade 3, as graded by clinician assessment) in only 13 percent and generally reversible. By 48 months, grade 1, 2, or 3 neuropathy was observed in only 12, 3, and 0.7 percent of patients, respectively. (See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer", section on 'FOLFOX and the MOSAIC trial'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other studies</strong> – Other studies utilizing patient-reported outcome measures have suggested that the prevalence of persisting neuropathy is higher in long-term survivors [<a href="#rid142">142,160,162-164</a>]. As an example, in one systematic review of 27 studies, the pooled prevalence of persistent CIPN of any grade at 6, 12, 24, and 36 months after oxaliplatin-containing chemotherapy was 58, 45, 32, and 24 percent, respectively [<a href="#rid164">164</a>]. (See  <a class="medical medical_review" href="/d/html/14230.html" rel="external">"Approach to the long-term survivor of colorectal cancer", section on 'Oxaliplatin-induced peripheral neuropathy'</a>.)</p><p></p><p class="headingAnchor" id="H1201468062"><span class="h4">Prevention and treatment</span><span class="headingEndMark"> — </span>Multiple approaches have been used to prevent or minimize the cumulative neurotoxicity associated with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> therapy. These include dose reduction, interrupting and reintroducing oxaliplatin therapy, lengthening the duration of infusion, supplemental intravenous calcium and magnesium infusions, and various pharmacologic agents.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When appropriate in the clinical setting, interspersing a non-oxaliplatin-containing "maintenance" chemotherapy regimen with the <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> regimen in patients undergoing palliative chemotherapy for metastatic CRC can forestall the development of neuropathy and is reasonable. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Stopping and reintroducing oxaliplatin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are insufficient data to support a neuroprotective benefit from lengthening the duration of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> infusion, and it cannot be recommended. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Lengthened infusion duration'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are no established pharmacologic agents that can be recommended for the prevention of oxaliplatin-induced peripheral neuropathy. Guidelines for prevention and management of chemotherapy-induced peripheral neuropathy from the American Society of Clinical Oncology (ASCO) [<a href="#rid165">165</a>] recommend against the use of IV calcium/magnesium supplementation or any other neuroprotective agent for patients receiving oxaliplatin-based therapy.</p><p></p><p class="bulletIndent1">These issues are all addressed separately. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Oxaliplatin'</a> and  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Vitamins, minerals, and dietary supplements'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – In general:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose reduction guidelines for patients who develop ≥grade 2  (<a class="graphic graphic_table graphicRef78736" href="/d/graphic/78736.html" rel="external">table 6</a>) neuropathy during treatment are provided in the US Food and Drug Association (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D3c740b43-f396-4998-bc66-6964a21f7161&amp;token=vQq9v%2BmiSIXZb%2Fzzb13YPCm9kkPoXgdxfksvSaONDy4AyX0%2F7XFmZPUp642eHVk8GiJwrLHHdS7jiJyZFzvnqRvBUyFfM6PWJQa6GZH08bv2%2Feua3%2F%2F%2BvXA6BOtcAh%2F8&amp;TOPIC_ID=2826" target="_blank">FDA)-approved manufacturer's labeling</a> information. If symptoms increase in severity or the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amelioration of symptoms from the chronic neuropathy, including pain, may be achieved through use of antidepressants such as <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>. For symptomatic patients who fail to respond to duloxetine, other adjuvant analgesics (eg, tricyclic antidepressants, anticonvulsants such as <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>), opioids, physical modalities such as cutaneous electrical stimulation, and/or interventional procedures may be indicated.</p><p></p><p class="bulletIndent1">Symptomatic treatment for chemotherapy-induced peripheral neuropathy is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Symptomatic treatment'</a> and  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with neuropathic pain'</a> and  <a class="medical medical_review" href="/d/html/14249.html" rel="external">"Rehabilitative and integrative therapies for pain in patients with cancer", section on 'Other modalities'</a> and  <a class="medical medical_review" href="/d/html/14248.html" rel="external">"Interventional therapies for chronic pain"</a>.)</p><p></p><p class="headingAnchor" id="H645668"><span class="h3">Reversible posterior leukoencephalopathy syndrome</span><span class="headingEndMark"> — </span>Reversible posterior leukoencephalopathy syndrome (RPLS) has been observed rarely in clinical trials (&lt;0.1 percent) and in postmarketing experience. Signs and symptoms include headache, altered mental function, seizures, and visual changes, with or without hypertension. The diagnosis is confirmed by brain imaging.</p><p class="headingAnchor" id="H1073930582"><span class="h3">Other complications</span><span class="headingEndMark"> — </span>Guillain-Barré syndrome has been rarely reported [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3575065990"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115871.html" rel="external">"Society guideline links: Neuropathic pain"</a> and  <a class="medical medical_society_guidelines" href="/d/html/119434.html" rel="external">"Society guideline links: Cancer pain"</a> and  <a class="medical medical_society_guidelines" href="/d/html/126560.html" rel="external">"Society guideline links: Hearing loss and hearing disorders in adults"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Among the widely used anticancer drugs, the platinum compounds <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> are most commonly associated with neurotoxicity. (See <a class="local">'Cisplatin'</a> above and <a class="local">'Oxaliplatin'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin</strong> – The range of cisplatin-induced neurotoxicity includes peripheral neuropathy, ototoxicity (hearing impairment and tinnitus), the Raynaud phenomenon, myelotoxicity, and encephalopathy; the most common are peripheral neuropathy and ototoxicity. (See <a class="local">'Cisplatin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The peripheral neuropathy is typically symmetrical, predominantly sensory and usually begins in the toes and fingers, spreading proximally to affect the legs and arms. It is cumulative and typically develops only after a cumulative dose of 300 mg/m<sup>2</sup> is reached. (See <a class="local">'Clinical and electrophysiologic manifestations'</a> above and <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The differential diagnosis includes paraneoplastic neuropathies and those associated with autoimmune disorders, hand-foot syndrome, and symptomatic electrolyte disorders caused by <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>There is no effective preventive strategy. If neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Some patients may benefit from a switch to <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>. Most patients improve over time, although recovery is often incomplete. Symptoms associated with chronic neuropathy, including pain, may respond to antidepressants such as <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>. (See <a class="local">'Natural history, prevention, and treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ototoxicity is the second most common cisplatin-related neurotoxic effect; it is characterized by a dose-dependent, typically bilateral, irreversible, high-frequency sensorineural hearing loss, often accompanied by tinnitus. Ototoxicity can be particularly severe in children. (See <a class="local">'Ototoxicity'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Particularly in children receiving platinum agents, monitoring and early detection of hearing loss with the opportunity for treatment modification may minimize the risk of severe impairment in the frequencies required for speech recognition.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest the use of <a class="drug drug_general" data-topicid="9939" href="/d/drug information/9939.html" rel="external">sodium thiosulfate</a> (STS) for children receiving <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> monotherapy for a variety of non-metastatic malignancies, including standard-risk hepatoblastoma (cumulative dose 480 mg/m<sup>2</sup>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, the safety and efficacy of this approach in patients with non-metastatic hepatoblastoma who receive lower cumulative doses is not established. (See  <a class="medical medical_review" href="/d/html/130011.html" rel="external">"Overview of hepatoblastoma", section on 'Approaches to minimizing long-term treatment-related toxicity'</a>.)</p><p></p><p class="bulletIndent3">The available evidence is insufficient to support the routine use of STS in children receiving <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> for treatment of a metastatic malignancy or in adults receiving cisplatin, or for any other pharmacologic agent to prevent cisplatin ototoxicity. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>More rarely, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is associated with a number of other neurologic complications, including arterial thromboembolic events, encephalopathy (rare), vestibulopathy, and hiccups. (See <a class="local">'Encephalopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carboplatin</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral neuropathy and central nervous system toxicity are uncommon when <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is given at conventional doses  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>). However, a severe neuropathy can develop after a higher than standard dose of carboplatin, as is used in the setting of high-dose therapy with hematopoietic cell transplantation. (See <a class="local">'Carboplatin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The administration of <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> to children treated for retinoblastoma usually does not lead to acute or subacute hearing loss; however, higher rates have been seen in very young patients, particularly when dosing of carboplatin was based upon body surface area rather than body weight alone. (See <a class="local">'Hearing loss'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxaliplatin</strong> – Two distinct neuropathies are reported in patients receiving <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (see <a class="local">'Oxaliplatin'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The majority of treated patients develop an acute neurosensory complex within 24 to 72 hours after each dose consisting of sensitivity to touching cold objects; paresthesias and dysesthesias of the hands, feet, and perioral region; unusual cold-induced pharyngolaryngeal dysesthesias; and muscle cramps. Symptoms generally recur with each dose. (See <a class="local">'Acute neurotoxicity'</a> above.)</p><p></p><p class="bulletIndent2">Supplemental calcium and magnesium infusions are of no preventive benefit and should not be offered to patients receiving <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> therapy. This subject is addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Vitamins, minerals, and dietary supplements'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A dose-limiting late-onset neuropathy that is cumulative, dose-dependent, and typically consists of a sensory, symmetric distal axonal neuropathy without motor involvement  (<a class="graphic graphic_table graphicRef67516" href="/d/graphic/67516.html" rel="external">table 2</a>). (See <a class="local">'Cumulative sensory neuropathy'</a> above.)</p><p></p><p class="bulletIndent2">Both the incidence and severity are predominantly related to cumulative dose, although other factors (eg, diabetes, severity of acute neuropathy) may contribute. (See <a class="local">'Impact of dose intensity and length of treatment'</a> above and <a class="local">'Other factors'</a> above.)</p><p></p><p class="bulletIndent2">Dose reduction guidelines for patients who develop ≥grade 2  (<a class="graphic graphic_table graphicRef78736" href="/d/graphic/78736.html" rel="external">table 6</a>) axonal neuropathy during treatment are provided in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D3c740b43-f396-4998-bc66-6964a21f7161&amp;token=vQq9v%2BmiSIXZb%2Fzzb13YPCm9kkPoXgdxfksvSaONDy4AyX0%2F7XFmZPUp642eHVk8GiJwrLHHdS7jiJyZFzvnqRvBUyFfM6PWJQa6GZH08bv2%2Feua3%2F%2F%2BvXA6BOtcAh%2F8&amp;TOPIC_ID=2826" target="_blank">US Food and Drug Association (FDA)-approved manufacturer's labeling information</a>. If symptoms increase in severity or the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.</p><p></p><p class="bulletIndent2">In general, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> neurotoxicity improves after discontinuation of therapy. However, it may continue to worsen for a few months after treatment is discontinued, and recovery is often incomplete. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent2">There are no pharmacologic agents that can be recommended to prevent the development of neuropathy. When appropriate in the clinical setting, interspersing a non-oxaliplatin-containing "maintenance" chemotherapy regimen with the <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> regimen in patients undergoing palliative chemotherapy for metastatic colorectal cancer can forestall the development of neuropathy and is reasonable. (See <a class="local">'Prevention and treatment'</a> above and  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Stopping and reintroducing oxaliplatin'</a>.)</p><p></p><p class="bulletIndent2">Symptoms associated with chronic neuropathy, including pain, may respond to antidepressants such as <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Dietrich J, Wen PY. Neurologic complications of chemotherapy. In: Cancer Neurology in Clinical Practice, 2nd ed, Schiff D, Kesari S, Wen PY (Eds), Humana Press, Totowa 2008. p.287.</li><li class="breakAll">DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic Complications of Cancer, 2nd ed, Oxford University Press, New York 2009. p.447.</li><li><a class="nounderline abstract_t">Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009; 6:596.</a></li><li><a class="nounderline abstract_t">Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63:761.</a></li><li><a class="nounderline abstract_t">van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322:89.</a></li><li><a class="nounderline abstract_t">Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 66:1117.</a></li><li><a class="nounderline abstract_t">von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 2001; 85:823.</a></li><li><a class="nounderline abstract_t">Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012; 82:51.</a></li><li><a class="nounderline abstract_t">Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130:1076.</a></li><li><a class="nounderline abstract_t">Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34:934.</a></li><li><a class="nounderline abstract_t">Glendenning JL, Barbachano Y, Norman AR, et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010; 116:2322.</a></li><li><a class="nounderline abstract_t">van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66:1697.</a></li><li><a class="nounderline abstract_t">Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010; 10:54.</a></li><li><a class="nounderline abstract_t">Oldenburg J, Kraggerud SM, Brydøy M, et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007; 5:70.</a></li><li><a class="nounderline abstract_t">Gu J, Lu H, Chen C, et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer 2021; 29:7461.</a></li><li><a class="nounderline abstract_t">Hilkens PH, van der Burg ME, Moll JW, et al. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. Eur J Cancer 1995; 31A:678.</a></li><li class="breakAll">Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, Davis FA (Ed), Philadelphia 1995. p.282.</li><li><a class="nounderline abstract_t">Eeles R, Tait DM, Peckham MJ. Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep 1986; 70:905.</a></li><li><a class="nounderline abstract_t">Daugaard GK, Petrera J, Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand 1987; 76:86.</a></li><li><a class="nounderline abstract_t">Cavaletti G, Marzorati L, Bogliun G, et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992; 69:203.</a></li><li><a class="nounderline abstract_t">Stuart-Harris R, Ponder BA, Wrigley PF. Tetany associated with cis-platin. Lancet 1980; 2:1303.</a></li><li><a class="nounderline abstract_t">Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27:992.</a></li><li><a class="nounderline abstract_t">McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005; 18:305.</a></li><li><a class="nounderline abstract_t">Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998; 101:2842.</a></li><li><a class="nounderline abstract_t">Zhang H, Mizumachi T, Carcel-Trullols J, et al. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis 2007; 28:1629.</a></li><li><a class="nounderline abstract_t">McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 2002; 9:220.</a></li><li><a class="nounderline abstract_t">Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 2009; 30:312.</a></li><li><a class="nounderline abstract_t">Albany C, Dockter T, Wolfe E, et al. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer 2021; 29:833.</a></li><li><a class="nounderline abstract_t">Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012; 30:300.</a></li><li><a class="nounderline abstract_t">Dolan ME, El Charif O, Wheeler HE, et al. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res 2017; 23:5757.</a></li><li><a class="nounderline abstract_t">Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 2006; 24:918.</a></li><li><a class="nounderline abstract_t">Langer T, am Zehnhoff-Dinnesen A, Radtke S, et al. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci 2013; 34:458.</a></li><li><a class="nounderline abstract_t">van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev 2016; :CD010181.</a></li><li><a class="nounderline abstract_t">Nieves L, Currie J, Hoffman J, Sorosky JI. Ototoxicity after intraperitoneal chemotherapy: a case report. Int J Gynecol Cancer 2007; 17:1133.</a></li><li><a class="nounderline abstract_t">Landier W. Ototoxicity and cancer therapy. Cancer 2016; 122:1647.</a></li><li><a class="nounderline abstract_t">Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23:8588.</a></li><li><a class="nounderline abstract_t">Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol 2016; 34:2712.</a></li><li><a class="nounderline abstract_t">Beyea JA, Lau C, Cooke B, et al. Long-Term Incidence and Predictors of Significant Hearing Loss Requiring Hearing Assistive Devices Among Childhood Cancer Survivors: A Population-Based Study. J Clin Oncol 2020; 38:2639.</a></li><li><a class="nounderline abstract_t">Moke DJ, Luo C, Millstein J, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health 2021; 5:274.</a></li><li><a class="nounderline abstract_t">Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25:708.</a></li><li><a class="nounderline abstract_t">Ross CJ, Katzov-Eckert H, Dubé MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41:1345.</a></li><li><a class="nounderline abstract_t">Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30:2408.</a></li><li><a class="nounderline abstract_t">Yang JJ, Lim JY, Huang J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 2013; 94:252.</a></li><li><a class="nounderline abstract_t">Pussegoda K, Ross CJ, Visscher H, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013; 94:243.</a></li><li><a class="nounderline abstract_t">Riedemann L, Lanvers C, Deuster D, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 2008; 8:23.</a></li><li><a class="nounderline abstract_t">Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000; 11:639.</a></li><li><a class="nounderline abstract_t">Caronia D, Patiño-García A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009; 9:347.</a></li><li><a class="nounderline abstract_t">Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005; 11:1534.</a></li><li><a class="nounderline abstract_t">Xu H, Robinson GW, Huang J, et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 2015; 47:263.</a></li><li><a class="nounderline abstract_t">Drögemöller BI, Monzon JG, Bhavsar AP, et al. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol 2017.</a></li><li><a class="nounderline abstract_t">Wheeler HE, Gamazon ER, Frisina RD, et al. Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res 2017; 23:3325.</a></li><li><a class="nounderline abstract_t">Low WK, Toh ST, Wee J, et al. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006; 24:1904.</a></li><li><a class="nounderline abstract_t">Kolinsky DC, Hayashi SS, Karzon R, et al. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol 2010; 32:119.</a></li><li><a class="nounderline abstract_t">Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40:2445.</a></li><li><a class="nounderline abstract_t">Stöhr W, Langer T, Kremers A, et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005; 23:201.</a></li><li><a class="nounderline abstract_t">Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107:417.</a></li><li><a class="nounderline abstract_t">Meijer AJM, Li KH, Brooks B, et al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer 2022; 128:169.</a></li><li><a class="nounderline abstract_t">van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 2016; :CD010885.</a></li><li><a class="nounderline abstract_t">Bass JK, Liu W, Banerjee P, et al. Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. JAMA Oncol 2020; 6:1363.</a></li><li><a class="nounderline abstract_t">Phillips NS, Duke ES, Schofield HT, Ullrich NJ. Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact. J Clin Oncol 2021; 39:1752.</a></li><li><a class="nounderline abstract_t">Clemens E, van den Heuvel-Eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol 2019; 20:e29.</a></li><li class="breakAll">Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, version 5.0 (October 2018), available online at http://www.survivorshipguidelines.org/ (Accessed on February 10, 2022).</li><li><a class="nounderline abstract_t">Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007; 226:157.</a></li><li><a class="nounderline abstract_t">Hellberg V, Wallin I, Eriksson S, et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101:37.</a></li><li><a class="nounderline abstract_t">Knight KR, Chen L, Freyer D, et al. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol 2017; 35:440.</a></li><li><a class="nounderline abstract_t">Bass JK, Bhagat SP. Challenges in ototoxicity monitoring in the pediatric oncology population. J Am Acad Audiol 2014; 25:760.</a></li><li><a class="nounderline abstract_t">Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25:1190.</a></li><li><a class="nounderline abstract_t">Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, et al. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol 2021; 7:1550.</a></li><li><a class="nounderline abstract_t">Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 2005; 314:1052.</a></li><li><a class="nounderline abstract_t">Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001; 7:493.</a></li><li><a class="nounderline abstract_t">Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): A multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18:63.</a></li><li><a class="nounderline abstract_t">Brock PR, Maibach R, Childs M, et al. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med 2018; 378:2376.</a></li><li><a class="nounderline abstract_t">Orgel E, Villaluna D, Krailo MD, et al. Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431. Lancet Oncol 2022; 23:570.</a></li><li><a class="nounderline abstract_t">Chen CH, Huang CY, Lin HH, et al. Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4:e2118895.</a></li><li class="breakAll">FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. US Food and Drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sodium-thiosulfate-reduce-risk-ototoxicity-associated-cisplatin-pediatric-patients (Accessed on September 21, 2022).</li><li class="breakAll">PEDMARK® (sodium thiosulfate injection), for intravenous use. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212937s000lbl.pdf (Accessed on September 21, 2022).</li><li><a class="nounderline abstract_t">Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26:3749.</a></li><li><a class="nounderline abstract_t">Gurney JG, Bass JK, Onar-Thomas A, et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol 2014; 16:848.</a></li><li><a class="nounderline abstract_t">Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer 2005; 104:841.</a></li><li><a class="nounderline abstract_t">Katzenstein HM, Chang KW, Krailo M, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 2009; 115:5828.</a></li><li><a class="nounderline abstract_t">Gallegos-Castorena S, Martínez-Avalos A, Mohar-Betancourt A, et al. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 2007; 24:403.</a></li><li><a class="nounderline abstract_t">van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 2016; 9:CD009219.</a></li><li><a class="nounderline abstract_t">Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.</a></li><li><a class="nounderline abstract_t">Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004; 114:538.</a></li><li><a class="nounderline abstract_t">Villani V, Zucchella C, Cristalli G, et al. Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial. Head Neck 2016; 38 Suppl 1:E2118.</a></li><li><a class="nounderline abstract_t">Marshak T, Steiner M, Kaminer M, et al. Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone: A Randomized Controlled Study. Otolaryngol Head Neck Surg 2014; 150:983.</a></li><li><a class="nounderline abstract_t">Riga MG, Chelis L, Kakolyris S, et al. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Am J Clin Oncol 2013; 36:1.</a></li><li><a class="nounderline abstract_t">Yoo J, Hamilton SJ, Angel D, et al. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope 2014; 124:E87.</a></li><li><a class="nounderline abstract_t">Sarafraz Z, Ahmadi A, Daneshi A. Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial. Int Tinnitus J 2018; 22:40.</a></li><li><a class="nounderline abstract_t">Freyer DR, Brock P, Knight K, et al. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. Lancet Child Adolesc Health 2019; 3:578.</a></li><li><a class="nounderline abstract_t">Gandara DR, Nahhas WA, Adelson MD, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995; 13:490.</a></li><li><a class="nounderline abstract_t">Paredes J, Hong WK, Felder TB, et al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 1988; 6:955.</a></li><li><a class="nounderline abstract_t">Verma S, Stewart DJ, Maroun JA, Nair RC. A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am J Clin Oncol 1990; 13:119.</a></li><li><a class="nounderline abstract_t">Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28:1788.</a></li><li><a class="nounderline abstract_t">Freyer DR, Brock PR, Chang KW, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health 2020; 4:141.</a></li><li><a class="nounderline abstract_t">Newton HB, Page MA, Junck L, Greenberg HS. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 1989; 7:39.</a></li><li><a class="nounderline abstract_t">Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998; 19:415.</a></li><li><a class="nounderline abstract_t">Lyass O, Lossos A, Hubert A, et al. Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs 1998; 9:100.</a></li><li><a class="nounderline abstract_t">Otsuka F, Hayashi Y, Ogura T, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin. Intern Med 1996; 35:290.</a></li><li><a class="nounderline abstract_t">Sthoeger ZM, Breisilovsky S, Sthoeger D, et al. Syndrome of inappropriate antidiuretic hormone secretion following cis-dichlorodiammineplatinum II in a patient with laryngeal carcinoma. Eur J Med 1993; 2:175.</a></li><li><a class="nounderline abstract_t">Amidi A, Hosseini SMH, Leemans A, et al. Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy. J Natl Cancer Inst 2017; 109.</a></li><li><a class="nounderline abstract_t">Liaw CC, Wang CH, Chang HK, et al. Cisplatin-related hiccups: male predominance, induction by dexamethasone, and protection against nausea and vomiting. J Pain Symptom Manage 2005; 30:359.</a></li><li><a class="nounderline abstract_t">Pappa E, Berzero G, Herlin B, et al. Guillain-Barré Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature. Oncologist 2020; 25:e194.</a></li><li><a class="nounderline abstract_t">Dropcho EJ, Rosenfeld SS, Vitek J, et al. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 1998; 36:191.</a></li><li><a class="nounderline abstract_t">Yakirevitch A, Talmi YP, Baram Y, et al. Effects of cisplatin on olfactory function in cancer patients. Br J Cancer 2005; 92:1611.</a></li><li><a class="nounderline abstract_t">Castellanos AM, Glass JP, Yung WK. Regional nerve injury after intra-arterial chemotherapy. Neurology 1987; 37:834.</a></li><li><a class="nounderline abstract_t">Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998; 64:667.</a></li><li><a class="nounderline abstract_t">Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9:13.</a></li><li><a class="nounderline abstract_t">Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012; 30:1034.</a></li><li><a class="nounderline abstract_t">Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol 2014; 32:527.</a></li><li><a class="nounderline abstract_t">Cavaletti G, Bogliun G, Zincone A, et al. Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res 1998; 18:3797.</a></li><li><a class="nounderline abstract_t">Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 2008; 50:223.</a></li><li><a class="nounderline abstract_t">Smits C, Swen SJ, Theo Goverts S, et al. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer 2006; 42:492.</a></li><li><a class="nounderline abstract_t">Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009; 52:637.</a></li><li><a class="nounderline abstract_t">Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157.</a></li><li><a class="nounderline abstract_t">Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989; 64:1017.</a></li><li><a class="nounderline abstract_t">Vieillot S, Pouessel D, de Champfleur NM, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol 2007; 18:608.</a></li><li><a class="nounderline abstract_t">Stewart DJ, Belanger JM, Grahovac Z, et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery 1992; 30:512.</a></li><li><a class="nounderline abstract_t">Oh SY, Wasif N, Garcon MC, et al. Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. JOP 2013; 14:676.</a></li><li><a class="nounderline abstract_t">Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002; 94:2434.</a></li><li><a class="nounderline abstract_t">Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity. Oncology 2009; 77:342.</a></li><li><a class="nounderline abstract_t">Pinedo DM, Shah-Khan F, Shah PC. Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. J Clin Oncol 2007; 25:5320.</a></li><li><a class="nounderline abstract_t">Morís G, Ribacoba R, González C. Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine. J Neurol 2007; 254:534.</a></li><li><a class="nounderline abstract_t">Skelton MR, Goldberg RM, O'Neil BH. A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 2007; 6:386.</a></li><li><a class="nounderline abstract_t">Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 2013; 119:438.</a></li><li><a class="nounderline abstract_t">Pachman DR, Qin R, Seisler DK, et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol 2015; 33:3416.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011; 29:1472.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007; 13:399.</a></li><li><a class="nounderline abstract_t">Adenis A, Mailliez A, Rigot JM, et al. Recurrent priapism related to oxaliplatin infusion. J Clin Oncol 2008; 26:1016.</a></li><li><a class="nounderline abstract_t">Saif MW, Hashmi S. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol 2008; 61:349.</a></li><li><a class="nounderline abstract_t">Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29:21.</a></li><li><a class="nounderline abstract_t">Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 2008; 61:105.</a></li><li><a class="nounderline abstract_t">Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009; 132:2712.</a></li><li><a class="nounderline abstract_t">Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85:2293.</a></li><li><a class="nounderline abstract_t">Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20:1767.</a></li><li><a class="nounderline abstract_t">Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29:387.</a></li><li><a class="nounderline abstract_t">Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007; 13:6359.</a></li><li><a class="nounderline abstract_t">Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009; 27:1243.</a></li><li><a class="nounderline abstract_t">Park SB, Lin CS, Krishnan AV, et al. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One 2011; 6:e18469.</a></li><li><a class="nounderline abstract_t">Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005; 146:1027.</a></li><li><a class="nounderline abstract_t">Dermitzakis EV, Kimiskidis VK, Eleftheraki A, et al. The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system. Eur J Neurol 2014; 21:1471.</a></li><li><a class="nounderline abstract_t">Bennett BK, Park SB, Lin CS, et al. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 2012; 20:2959.</a></li><li><a class="nounderline abstract_t">Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000; 11:1477.</a></li><li><a class="nounderline abstract_t">Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29:11.</a></li><li><a class="nounderline abstract_t">de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938.</a></li><li><a class="nounderline abstract_t">Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 2014; 85:392.</a></li><li><a class="nounderline abstract_t">Alejandro LM, Behrendt CE, Chen K, et al. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 2013; 36:331.</a></li><li><a class="nounderline abstract_t">Uwah AN, Ackler J, Leighton JC Jr, et al. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 2012; 11:275.</a></li><li><a class="nounderline abstract_t">Lee S, Ma C, Shi Q, et al. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. J Clin Oncol 2023; 41:1079.</a></li><li><a class="nounderline abstract_t">Yoshino T, Yamanaka T, Oki E, et al. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial. JAMA Oncol 2019; 5:1574.</a></li><li><a class="nounderline abstract_t">Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012; 23:3116.</a></li><li><a class="nounderline abstract_t">Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25:1247.</a></li><li><a class="nounderline abstract_t">Won HH, Lee J, Park JO, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 2012; 118:2828.</a></li><li><a class="nounderline abstract_t">Custodio A, Moreno-Rubio J, Aparicio J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 2014; 25:398.</a></li><li><a class="nounderline abstract_t">Lecomte T, Landi B, Beaune P, et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12:3050.</a></li><li><a class="nounderline abstract_t">Goekkurt E, Al-Batran SE, Hartmann JT, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 2009; 27:2863.</a></li><li><a class="nounderline abstract_t">Hong J, Han SW, Ham HS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 2011; 67:1323.</a></li><li><a class="nounderline abstract_t">Kanai M, Kawaguchi T, Kotaka M, et al. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Ann Oncol 2016; 27:1143.</a></li><li><a class="nounderline abstract_t">Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25:2205.</a></li><li><a class="nounderline abstract_t">Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012; 118:5614.</a></li><li><a class="nounderline abstract_t">André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109.</a></li><li><a class="nounderline abstract_t">Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013; 31:2699.</a></li><li><a class="nounderline abstract_t">Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006; 56:13.</a></li><li><a class="nounderline abstract_t">Teng C, Cohen J, Egger S, et al. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. Support Care Cancer 2022; 30:33.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020; 38:3325.</a></li></ol></div><div id="topicVersionRevision">Topic 2826 Version 77.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dietrich J, Wen PY. Neurologic complications of chemotherapy. In: Cancer Neurology in Clinical Practice, 2nd ed, Schiff D, Kesari S, Wen PY (Eds), Humana Press, Totowa 2008. p.287.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic Complications of Cancer, 2nd ed, Oxford University Press, New York 2009. p.447.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19707193" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neurological adverse effects caused by cytotoxic and targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19034447" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Central and peripheral nervous system toxicity of common chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2152972" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2169332" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556831" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21908200" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301082" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6330613" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Peripheral sensory neuropathy and cisplatin chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20225230" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2119878" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786980" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162130" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34085148" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7640038" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7640038" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2424594" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3673502" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1309303" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6108477" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tetany associated with cis-platin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16797073" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686959" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637718" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389610" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895373" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19428505" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Role of MAPKs in platinum-induced neuronal apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32500206" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184390" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28611204" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484702" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Relationship between cisplatin administration and the development of ototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769626" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Understanding platinum-induced ototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27486906" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Platinum-induced hearing loss after treatment for childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17433058" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ototoxicity after intraperitoneal chemotherapy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26859792" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ototoxicity and cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314621" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354478" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32463737" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-Term Incidence and Predictors of Significant Hearing Loss Requiring Hearing Assistive Devices Among Childhood Cancer Survivors: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33581749" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17228018" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19898482" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547603" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23820299" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588304" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457342" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11081456" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19434073" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746057" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25665007" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448657" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28039263" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622266" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20098336" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519518" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15945505" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16779793" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34490624" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27498707" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Different infusion durations for preventing platinum-induced hearing loss in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32729886" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association of Hearing Impairment With Neurocognition in Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33886374" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30614474" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30614474" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113254" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mechanisms of cisplatin-induced ototoxicity and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116379" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27937095" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25380122" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Challenges in ototoxicity monitoring in the pediatric oncology population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401008" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34383016" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15951398" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11297239" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27914822" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29924955" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35489339" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34338793" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34338793" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34338793" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669462" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24414535" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999362" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19813275" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17710657" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27669661" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018081" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15091231" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Vitamin E reduces cisplatin ototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26849799" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24618499" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22134515" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23946126" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29993216" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31160205" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7844610" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2836565" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2180271" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194861" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Practical grading system for evaluating cisplatin ototoxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31866182" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2547032" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Intra-arterial cisplatin for the treatment of malignant gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541291" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9491799" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cisplatin-induced non-convulsive encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8739784" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8261061" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Syndrome of inappropriate antidiuretic hormone secretion following cis-dichlorodiammineplatinum II in a patient with laryngeal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617869" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16256900" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cisplatin-related hiccups: male predominance, induction by dexamethasone, and protection against nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31615948" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Guillain-BarréSyndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525819" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827551" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effects of cisplatin on olfactory function in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3033546" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Regional nerve injury after intra-arterial chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9598687" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541678" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Carboplatin versus cisplatin in solid tumors: an analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370329" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Carboplatin-associated ototoxicity in children with retinoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419114" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854499" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278120" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376542" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Assessment of hearing in very young children receiving carboplatin for retinoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19148943" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679531" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Developmental pharmacology--drug disposition, action, and therapy in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2667747" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Carboplatin-associated thrombotic microangiopathic hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164233" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Reversible posterior leukoencephalopathy syndrome after carboplatin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1316564" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Phase I study of intracarotid administration of carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24216561" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015768" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20016227" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024878" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17361348" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17311705" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A case of oxaliplatin-related posterior reversible encephalopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22786764" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282635" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383290" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032978" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18281680" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Recurrent priapism related to oxaliplatin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17849118" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12422305" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17429632" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19745023" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11353042" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919233" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Acute oxaliplatin-induced peripheral nerve hyperexcitability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981738" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975148" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164207" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21494615" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16231011" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041285" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22426503" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Impact of oxaliplatin-induced neuropathy: a patient perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11142489" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12422304" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Oxaliplatin-related side effects: characteristics and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944126" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813745" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547012" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Predicting acute and persistent neuropathy associated with oxaliplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22682776" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : The effect of diabetes on oxaliplatin-induced peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36367997" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31513248" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22865779" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401013" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22020760" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24351404" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707601" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332728" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20734048" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069012" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470850" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22569841" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451431" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775951" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825773" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34410459" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663120" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
